AR006813A1 - Peptidos consistentes en 16 a 55 residuos de aminoacido, composicion farmaceutica que comprende a por lo menos uno de dichos peptidos, metodo dediagnostico para la deteccion de celulas t auto-reactivas activadas que utiliza a por lo menos uno de tales peptidos y equipo para pruebas utilizado en dicho - Google Patents
Peptidos consistentes en 16 a 55 residuos de aminoacido, composicion farmaceutica que comprende a por lo menos uno de dichos peptidos, metodo dediagnostico para la deteccion de celulas t auto-reactivas activadas que utiliza a por lo menos uno de tales peptidos y equipo para pruebas utilizado en dichoInfo
- Publication number
- AR006813A1 AR006813A1 ARP970101654A ARP970101654A AR006813A1 AR 006813 A1 AR006813 A1 AR 006813A1 AR P970101654 A ARP970101654 A AR P970101654A AR P970101654 A ARP970101654 A AR P970101654A AR 006813 A1 AR006813 A1 AR 006813A1
- Authority
- AR
- Argentina
- Prior art keywords
- sec
- seq
- peptides
- amino acid
- acid residues
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001413 amino acids Chemical group 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 210000001188 articular cartilage Anatomy 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Péptidos consistentes en 16 a 55 residuos de aminoácidos, dichos péptidos comprenden al menos una de las secuencias de aminooácidos LVCYYTSWS (N* ID SEC:60)FLCTHIIYS(N* ID SEC.:61) IIYSFANIS (N*ID. SEC.:62), LKTLLSVGG (N*ID.SEC.:63) FIKSVPPFL (N* ID SEC.:64),FDGLDLAWL (N*ID.SEC.:65), LYPGRRKQ (N*ID. SEC.:66),YDIAKISQH (N*ID SEC.:67), LDFISIMTY (N*ID.SEC.:68), FISIMTYDF (N*ID.SEC.:69), FRGQEDASP (N* ID.SEC.:70), YAVGYMLRL (N*ID. SEC.:71), MLRLGAPAS (N*ID.SEC.:72),LAYYEICDF (N* ID.SEC.:73), LRGATVHRT (N*ID. SEC.:74), YLKDRQLAG (N* ID SEC.:75) LAGAMVWAL (N* ID.SEC.:76), VWALDLDDF (N*ID. SEC.:77), LDLDDFQGS (N* ID.SEC.:78)YKLVCYYTSWSQYREG (N* ID SEC.:1), YTSWSQYREGDGSCFP (N* ID SEC.:2), LDRFLCTHIIYSFANI (N* ID SEC.:5), THIIYSFANISNDHID (N* ID SEC.:6),PNLKTLLSVGGWNFGS (N* ID.SEC.:12), NTQSRRTFIKSVPPFL (N*ID. SEC.:16), TFIKSVPPFLRTHGFD (N*ID.SEC.:17), PPFLRTHGFDGLDLAW (N*ID. SEC.:18),HGFDGLDLAWLYPGRR (N*ID.SEC.:19), DLAWLYPGRRDKQHFT (N*ID.SEC.:20),TIDSSYDIAKISQHLD (N*ID.SEC.:28), DIAKISQHLDFISIMT (N*ID.SEC.:29),QHLDFISIMTYDFHGA (N*ID.SEC.:30), SPLFRGQEDASPDRFS (N*ID.SEC.:34), DYAVGYMLRLGAPASK (N*ID.SEC.:37), MLRLGAPASKLVMGIP (N*ID.SEC.:38),PASKLVMGIPTFGRSF (N*ID.SEC.:39), GTLAYYEICDFLRGAT (N*ID.SEC.:46), EICDFLRGATVHRTLG (N*ID.SEC.:47), RGATVHRTLGQQVPYA (N*ID.SEC.:48),VKSKVQYLKDRQLAGA (N*ID.SEC.:53), YLKDRQLAGAMVWALD (N*ID.SEC.:54), LAGAMVWALDLDDFQG (N*ID.SEC.:55), WALDLDDFQGSFCGQD (N*ID.SEC.:56),o DFQGSFCGQDLRFPLT (N*ID.SEC.:57). Los péptidos pueden utilizarse en el tratamiento de la destrucción intermediada por célula T del cartílago articularLa administración de composiciones farmacéuticas basadas en estos péptidos también incluidas en la invención, puede ser utilizada para inducirla
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96201106 | 1996-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR006813A1 true AR006813A1 (es) | 1999-09-29 |
Family
ID=8223915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970101654A AR006813A1 (es) | 1996-04-24 | 1997-04-24 | Peptidos consistentes en 16 a 55 residuos de aminoacido, composicion farmaceutica que comprende a por lo menos uno de dichos peptidos, metodo dediagnostico para la deteccion de celulas t auto-reactivas activadas que utiliza a por lo menos uno de tales peptidos y equipo para pruebas utilizado en dicho |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6184204B1 (es) |
| EP (1) | EP0920451A1 (es) |
| JP (1) | JP2000510106A (es) |
| KR (1) | KR20000010561A (es) |
| CN (1) | CN1216551A (es) |
| AR (1) | AR006813A1 (es) |
| AU (1) | AU719481B2 (es) |
| BR (1) | BR9708744A (es) |
| CA (1) | CA2251680A1 (es) |
| CZ (1) | CZ340698A3 (es) |
| HU (1) | HUP9901375A3 (es) |
| IL (1) | IL120561A0 (es) |
| NO (1) | NO984937L (es) |
| NZ (1) | NZ332427A (es) |
| PL (1) | PL329618A1 (es) |
| RU (1) | RU2199548C2 (es) |
| TR (1) | TR199802135T2 (es) |
| TW (1) | TW575583B (es) |
| WO (1) | WO1997040068A1 (es) |
| ZA (1) | ZA973071B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1310724A (zh) | 1998-07-23 | 2001-08-29 | 阿克佐诺贝尔公司 | 用于自身免疫疾病的免疫疗法中的新型肽 |
| HUP0203504A3 (en) * | 1999-10-18 | 2005-03-29 | Akzo Nobel Nv | Modified peptides and peptidomimetics for use in immunotherapy |
| IL132611A0 (en) | 1999-10-27 | 2001-03-19 | Yeda Res & Dev | Synthetic genes and polypeptides and pharmaceutical compositions comprising them |
| PT1309591E (pt) | 2000-08-14 | 2007-04-30 | Ortho Mcneil Pharm Inc | Pirazoles substituídos |
| US7002985B2 (en) * | 2001-01-16 | 2006-02-21 | Motorola, Inc. | Method and apparatus for organizing and scheduling multimedia data transfers over a wireless channel |
| CN101072875B (zh) * | 2004-12-07 | 2011-05-18 | 东丽株式会社 | 新型癌抗原肽及其用途 |
| AU2006218237B2 (en) * | 2005-02-28 | 2012-01-12 | Bio-Y A/S | YKL-40 monoclonal antibodies |
| FR2908654B1 (fr) | 2006-11-20 | 2014-04-04 | Oreal | Utilisation cosmetique de proteines de type chitinase |
| ES2536465T3 (es) * | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| RU2008140688A (ru) * | 2008-10-15 | 2010-04-20 | Михаил Аркадьевич Шурдов (RU) | Иммуносупрессивный пептид |
| WO2010142041A1 (en) | 2009-06-11 | 2010-12-16 | The University Of Guelph | Serine rich peptides having antioxidative stress properties |
| WO2011050471A1 (en) | 2009-10-28 | 2011-05-05 | University Of Manitoba | Yellow pea seed protein-derived peptides |
| KR101947529B1 (ko) | 2010-05-31 | 2019-02-13 | 런던 헬스 사이언시스 센터 리서치 인코포레이티드 | Rhamm 결합 펩타이드 |
| EP3565596A4 (en) | 2017-01-05 | 2020-12-16 | Brown University | PROCESSES AND COMPOSITIONS RELATING TO ANTI-CHI3LI ANTIBODY REAGENTS |
| US10766968B2 (en) | 2017-08-23 | 2020-09-08 | Brown University | Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2164498C (en) * | 1993-07-09 | 2007-09-11 | Paul A. Price | Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices |
| IL115744A (en) * | 1994-10-27 | 2000-07-16 | Akzo Nobel Nv | Peptides comprising a subsequence of human cartilage glycoprotein - 39 |
-
1997
- 1997-03-31 TW TW86104092A patent/TW575583B/zh not_active IP Right Cessation
- 1997-03-31 IL IL12056197A patent/IL120561A0/xx unknown
- 1997-04-10 ZA ZA973071A patent/ZA973071B/xx unknown
- 1997-04-22 TR TR1998/02135T patent/TR199802135T2/xx unknown
- 1997-04-22 BR BR9708744A patent/BR9708744A/pt not_active Application Discontinuation
- 1997-04-22 CZ CZ983406A patent/CZ340698A3/cs unknown
- 1997-04-22 KR KR1019980708415A patent/KR20000010561A/ko not_active Application Discontinuation
- 1997-04-22 HU HU9901375A patent/HUP9901375A3/hu unknown
- 1997-04-22 WO PCT/EP1997/002051 patent/WO1997040068A1/en not_active Application Discontinuation
- 1997-04-22 AU AU27685/97A patent/AU719481B2/en not_active Ceased
- 1997-04-22 CA CA002251680A patent/CA2251680A1/en not_active Abandoned
- 1997-04-22 US US09/171,705 patent/US6184204B1/en not_active Expired - Fee Related
- 1997-04-22 CN CN97194031A patent/CN1216551A/zh active Pending
- 1997-04-22 EP EP97921707A patent/EP0920451A1/en not_active Withdrawn
- 1997-04-22 NZ NZ332427A patent/NZ332427A/xx unknown
- 1997-04-22 RU RU98121402/04A patent/RU2199548C2/ru not_active IP Right Cessation
- 1997-04-22 PL PL97329618A patent/PL329618A1/xx unknown
- 1997-04-22 JP JP09537744A patent/JP2000510106A/ja not_active Ceased
- 1997-04-24 AR ARP970101654A patent/AR006813A1/es unknown
-
1998
- 1998-10-23 NO NO984937A patent/NO984937L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO984937D0 (no) | 1998-10-23 |
| TR199802135T2 (xx) | 1999-01-18 |
| NZ332427A (en) | 2000-03-27 |
| RU2199548C2 (ru) | 2003-02-27 |
| HUP9901375A3 (en) | 2000-10-30 |
| TW575583B (en) | 2004-02-11 |
| AU719481B2 (en) | 2000-05-11 |
| CN1216551A (zh) | 1999-05-12 |
| US6184204B1 (en) | 2001-02-06 |
| HUP9901375A2 (hu) | 1999-08-30 |
| WO1997040068A1 (en) | 1997-10-30 |
| BR9708744A (pt) | 1999-08-03 |
| KR20000010561A (ko) | 2000-02-15 |
| CZ340698A3 (cs) | 1999-02-17 |
| EP0920451A1 (en) | 1999-06-09 |
| PL329618A1 (en) | 1999-03-29 |
| CA2251680A1 (en) | 1997-10-30 |
| ZA973071B (en) | 1998-08-05 |
| AU2768597A (en) | 1997-11-12 |
| JP2000510106A (ja) | 2000-08-08 |
| NO984937L (no) | 1998-12-01 |
| IL120561A0 (en) | 1997-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR006813A1 (es) | Peptidos consistentes en 16 a 55 residuos de aminoacido, composicion farmaceutica que comprende a por lo menos uno de dichos peptidos, metodo dediagnostico para la deteccion de celulas t auto-reactivas activadas que utiliza a por lo menos uno de tales peptidos y equipo para pruebas utilizado en dicho | |
| ES2194376T3 (es) | Preparacion especifica de sitio de conjugados de polietilenglicol-grf. | |
| DK2014678T3 (da) | KDR-peptider og vacciner indeholdende disse | |
| NO20014508D0 (no) | Fremgangsmåte for acylering av peptider, og nye acyleringsmidler | |
| CO4890856A1 (es) | CICATRIZACION DE FRACTURAS USANDO ANALOGOS DE PTHrP | |
| AR108277A2 (es) | Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas | |
| ES2160485B1 (es) | Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen. | |
| AR002282A1 (es) | Polipeptidos utiles para detectar y/o tratar infestaciones con t. cruzi, composiciones farmaceuticas formuladas con dichos polipeptidos; equipos queincluyen dichos polipeptidos para el diagnostico de dichas infecciones, dna, vectores y celulas recombinantes transformadas con dicho dna. | |
| ATE114321T1 (de) | D-2-alkyltryptophan enthaltende biologisch aktive peptide. | |
| ES2193145T3 (es) | Proteinas procoagulants quimericas. | |
| DK1482042T3 (da) | Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren | |
| ATE78040T1 (de) | Oligopeptide sowie zwischenprodukte und verfahren zu ihrer herstellung. | |
| AU9315398A (en) | Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response | |
| NO20040222L (no) | Peptider til fjerning eller destruksjon av celler | |
| RU94036776A (ru) | Домен ингибитора протеазы, днк, вектор, клетка, способ получения ингибитора протеазы, фармацевтическая композиция, применение домена ингибитора протеазы | |
| BR9810478A (pt) | Análogos de hormÈnio glicoproteìna reticulados por dissulfeto e sua preparação e utilização | |
| BR9506377A (pt) | Peptídeo compreendendo uma subsequéncia de gp-39 hc proteina gp-39 hc ou peptideos composição farmacéutica uso da proteina gp-39 hc ou um ou mais dos peptídeos composição de diagnostico e processo de diagnóstico e kit de teste para a detecção de céçiças t auto-reativas ativadas | |
| CO5570658A2 (es) | Composicion y metodo para el tratamiento de la diabetes | |
| ATE174932T1 (de) | Modifizierte vip-derivate und sie enthaltende pharmazeutische zusammensetzungen | |
| BR9714376A (pt) | Antagonistas de somatostatina | |
| DK1095143T3 (da) | Inhibitor til diagnosticering og behandling af patienter med hæmofili A | |
| BR9811250A (pt) | Peptìdeos compreendendo uma epìtopo de célula t, especìfica para colágeno ii | |
| ES2127516T3 (es) | Peptidos para inhibir la liberacion de pepsina. | |
| AR018532A1 (es) | Proteinas sustancialmente puras que contienen analogos de la beta-lipoproteina (blt); aislados de acidos nucleicos que codifican dichas proteinas yformulaciones farmaceuticas que comprenden las proteinas | |
| ES2054208T3 (es) | Nuevos derivados gem-diaminicos y su empleo en la sintesis de peptidos retro-inversos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |